The USC Norris Comprehensive Cancer Center utilizes a well-established system for Planning and Evaluation that engages institutional leaders, Senior Leaders, Program Leaders, Shared Resources Directors, Cancer Center members and staff, advisors, and patient advocates. This effort includes well-tested and integrated mechanisms to monitor, evaluate, and adjust the Center?s Research Program activities, Shared Resource services, funding allocations, and strategic directions to ensure alignment with the Center?s vision and goals. Planning and Evaluation ensures that future directions are achievable and that resources and investments are targeted effectively, while providing the ability to respond to new opportunities and changes in the field. Our Planning and Evaluation process also is highly integrated with institutional planning and resource allocation activities to assure alignment and ability to capitalize on institutional investments. USC Norris employs a variety of Planning and Evaluation activities, supported in part by the CCSG funds. These include: External Advisory Board and ad hoc reviewers; Center-wide and Research Program retreats; Leadership Retreats; formal strategic planning; bi-weekly Executive Committee and Director?s Cabinet meetings; and monthly Leadership Council meetings. Under Dr. Gruber, strategic and programmatic planning and evaluation processes have been transformed and have become embedded in our culture. We have instituted a multi-year strategic plan that guides leadership decisions and investments. Leadership has been increasingly effective in defining and realizing the Cancer Center?s vision, using planning and evaluation mechanisms to guide decisions, assess progress, and make changes to assure success. In addition, the Executive Committee now conducts intensive annual program and core reviews, through which they carefully assess progress against milestones, future relevance, leadership and future aims.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-45
Application #
9838184
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Liu, Minmin; Zhang, Lian; Li, Hongtao et al. (2018) Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 68:1412-1428
Miller, Kimberly A; Ramirez, Cynthia N; Wojcik, Katherine Y et al. (2018) Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. Support Care Cancer 26:1305-1313
Belic, Jelena; Graf, Ricarda; Bauernhofer, Thomas et al. (2018) Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer 143:1236-1248
Tobin, Jessica; Allem, Jon-Patrick; Slaughter, Rhona et al. (2018) Posttraumatic growth among childhood cancer survivors: Associations with ethnicity, acculturation, and religious service attendance. J Psychosoc Oncol 36:175-188
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472

Showing the most recent 10 out of 842 publications